Technology
Health
Biotechnology

Scholar Rock

$19.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.88 (-4.40%) Today
-$0.88 (-4.40%) Today

Why Robinhood?

You can buy or sell Scholar Rock and other stocks, options, ETFs, and crypto commission-free!

About

Scholar Rock Holding Corporation Common Stock, also called Scholar Rock, is a biopharmaceutical company, which engages in developing and commercializing drug products. The company focuses on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Read More Its product candidate includes SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Employees
65
Headquarters
Cambridge, Massachusetts
Founded
2012
Market Cap
501.55M
Price-Earnings Ratio
Dividend Yield
Average Volume
86.14K
High Today
$20.79
Low Today
$18.88
Open Price
$19.86
Volume
343.44K
52 Week High
$30.00
52 Week Low
$13.09

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Pharmaceutical
2018 IPO
US

News

Markets InsiderMar 18

Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress

Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting Announced Strategic Collaboration with Gilead Sciences to Discover and Develop Highly Specific Inhibitors of TGFβ activation for the Treatment of Fibrotic Diseases Completed Initial Public Offering Raising Approximately $86 milli...

45
Associated PressMar 6

Scholar Rock to Participate in Upcoming Investor Conferences

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play...

100
MarketBeatFeb 27

Stock Price, News, & Analysis for Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.

36

Earnings

-$1.39
-$1.07
-$0.75
-$0.43
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.50 per share
Actual
-$0.43 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.